How it works

Light the tissue can use. Then the studies.

Class IV laser therapy is high-intensity laser therapy: a provider applies a high-power red or near-infrared beam to the skin. This page stays with what the mechanism papers and an FDA clearance actually say.

A soft red-to-crimson beam of light in a dark field.

Photobiomodulation and cellular energy

Red and near-infrared light in this setting is called photobiomodulation. A review from the Wellman Center for Photomedicine at Massachusetts General Hospital describes laser therapy’s potential to improve wound healing and to reduce pain, inflammation, and swelling, and notes that the wavelengths in use include many in the red and near infrared. (Chung et al., 2012)

The same center’s review of low-level laser therapy in neurorehabilitation puts the opening cellular events this way: “Mitochondria are thought to be the principal photoreceptors, and increased adenosine triphosphate, reactive oxygen species, intracellular calcium, and release of nitric oxide are the initial events.” (Hashmi et al., 2010)

A mechanisms review names cytochrome c oxidase — complex IV in the mitochondrial respiratory chain — as one of the most important chromophores, because it absorbs light into the near-infrared. The leading hypothesis in that review is that photons dissociate inhibitory nitric oxide from the enzyme, and electron transport, mitochondrial membrane potential, and ATP production increase. (de Freitas and Hamblin, 2016)

High-intensity laser therapy is the clinical form studied in the trials on this site: a high-power laser, described in an FDA clearance as Class IV energy, aimed at muscle and joint pain. The cellular account above comes from the photobiomodulation literature, which grew up around lower-power light as well as lasers. The trials linked from the conditions page are the ones that measured pain and function with high-intensity devices. (FDA 510(k) K083560)

Local circulation

In ten healthy men, a class 4 laser applied over the biceps at 3 watts increased forearm blood flow. By minute 4 of that exposure, flow had moved from 2.417 ± 0.342 to 2.794 ± 0.351 mL/min per 100 mL of tissue (p = 0.032). It was still higher 1 minute later (2.767 ± 0.358; p < 0.01) and 2 minutes later (2.657 ± 0.369; p = 0.022). The authors called that 3-watt dose an effective way to increase blood flow in the soft tissues. (Larkin et al., 2012)

Separately, the cleared intended use of devices in this category includes a temporary increase in local blood circulation, along with topical heating. That is a regulatory indication, not a promise that every session reproduces the laboratory measurement above. (FDA 510(k) K083560)

Inflammation

A review of photobiomodulation states: “One of the most reproducible effects of PBM is an overall reduction in inflammation.” The same paper identifies cytochrome c oxidase in mitochondria as a primary chromophore and lists an increase in ATP among the secondary effects of absorbing the light. It also reports that, in activated inflammatory cells, inflammatory markers decreased. (Hamblin, 2017)

Pain-signal modulation

A systematic review of non-ablative laser irradiation on peripheral nerve identified 44 studies. In 13 of 18 human studies, pulsed or continuous visible light, and continuous infrared light, slowed conduction velocity, reduced the amplitude of compound action potentials, or both. The reviewers wrote that these inhibitory effects may reduce acute pain by direct inhibition of peripheral nociceptors. The studies in that review are the lower-power and non-ablative literature, which is the body of work that proposed this pain-signal account. (Chow et al., 2011)

What “FDA-cleared” means here

FDA 510(k) K083560 cleared a therapeutic laser the summary describes as delivering Class IV energy. The regulatory class of that device is Class II, under 21 CFR 890.5500, product code ILY, an infrared lamp. Clearance means the FDA found the device substantially equivalent to an earlier device for the indications in the filing. It is not a premarket approval, and it is not an approval to treat a named diagnosis.

The indications for use, as written, are to emit energy in the infrared spectrum to provide topical heating for the purpose of elevating tissue temperature for: the temporary relief of minor muscle and joint pain and stiffness; minor arthritis pain; muscle spasm; the temporary increase in local blood circulation; and promoting relaxation of muscle. The filing marks the device for prescription use. (FDA 510(k) K083560)

See the condition-by-condition findings

Sources

  1. Chung et al., 2012. The nuts and bolts of low-level laser (light) therapy. Annals of Biomedical Engineering.
  2. Hashmi et al., 2010. Role of low-level laser therapy in neurorehabilitation. PM&R.
  3. de Freitas and Hamblin, 2016. Proposed mechanisms of photobiomodulation or low-level light therapy. IEEE Journal of Selected Topics in Quantum Electronics.
  4. FDA 510(k) K083560. 510(k) summary and indications for use: a therapeutic laser described as delivering Class IV energy, regulation 21 CFR 890.5500, product code ILY. U.S. Food and Drug Administration.
  5. Larkin et al., 2012. Limb blood flow after class 4 laser therapy. Journal of Athletic Training.
  6. Hamblin, 2017. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophysics.
  7. Chow et al., 2011. Inhibitory effects of laser irradiation on peripheral mammalian nerves and relevance to analgesic effects: a systematic review. Photomedicine and Laser Surgery.